Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Hexarelin, a growth hormone - releasing peptide, counteracts bone loss in gonadectomized male rats
Autore:
Sibilia, V; Cocchi, D; Pagani, F; Lattuada, N; Moro, GL; Pecile, A; Rubinacci, A; Muller, EE; Netti, C;
Indirizzi:
Univ Milan, Dept Pharmacol Chemotherapy & Med Toxicol, I-20129 Milan, Italy Univ Milan Milan Italy I-20129 erapy & Med Toxicol, I-20129 Milan, Italy Univ Brescia, Dept Biomed Sci & Biotechnol, I-25121 Brescia, Italy Univ Brescia Brescia Italy I-25121 & Biotechnol, I-25121 Brescia, Italy San Raffaele Sci Inst, Bone Metab Unit, I-20132 Milan, Italy San Raffaele Sci Inst Milan Italy I-20132 tab Unit, I-20132 Milan, Italy
Titolo Testata:
GROWTH HORMONE & IGF RESEARCH
fascicolo: 4, volume: 9, anno: 1999,
pagine: 219 - 227
SICI:
1096-6374(199908)9:4<219:HAGH-R>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
PYRIDINIUM CROSS-LINKS; OSTEOBLAST-LIKE CELLS; X-RAY ABSORPTIOMETRY; I IGF-I; OVARIECTOMIZED RATS; CORTICAL BONE; MINERAL DENSITY; SHORT-TERM; PARATHYROID-HORMONE; ELDERLY WOMEN;
Keywords:
hexarelin; growth hormone; rats; bone; gonadectomy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: Sibilia, V Univ Milan, Dept Pharmacol Chemotherapy & Med Toxicol, Via Vanvitelli 32, I-20129 Milan, Italy Univ Milan Via Vanvitelli 32 Milan Italy I-20129 Milan, Italy
Citazione:
V. Sibilia et al., "Hexarelin, a growth hormone - releasing peptide, counteracts bone loss in gonadectomized male rats", GROWTH H I, 9(4), 1999, pp. 219-227

Abstract

The age-related decline in growth hormone (GH) secretion has been implicated in the pathogenesis of involutional bone loss. Whether restoration of GHsecretion might be helpful in maintaining and/or improving bone mass during aging is still unsettled. The aim of the present study was to examine theeffects of 30-day treatment with hexarelin (HEXA, 50 mu g/kg subcutaneously b.i.d.), a highly effective GH-releasing compound, on bone metabolism andbone mineral density (BMD) in intact and osteopenic gonadectomized (GDX) mature male rats. Serum total alkaline phosphatase (ALP, bone formation marker) and bone resorption markers (lysylpyridinoline, LP and hydroxylysylpyridinoline, HP) were measured before and 7, 14 and 30 days after treatment. BMD was measured by dual-energy X-ray absorptiometry at lumbar vertebrae, femural metaphysis and diaphysis before and at the end of the experiment. In intact rats, HEXA significantly (P<0.05) decreased LP (-36.3%) and HP (-22.8%) excretion at day 7, whereas it did not change serum ALP activity and BMDs. In GDX rats, HEXA completely prevented the significant (P<0.01) increase in urinary excretion of both LP (+143.8%) and HP (+119.4%), the early decrease in ALP activity (-26.5%) and the significant (P<0.05) decrease in BMDs in the femural metaphysis (-7.9%) and lumbar vertebrae (-6.8%) caused by androgen deficiency. The bone-protective effects of HEXA could be attributed, at least in part, to its GH-releasing activity since chronic-treated rats maintained the GH response to an acute challenge with HEXA. The evidence that HEXA, unlike GH, inhibits bone resorption indicates that other mechanisms contribute to the bone sparing effect of HEXA. (C) 1999 Harcourt Publishers Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/02/20 alle ore 17:40:35